Cargando…

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

The design and baseline data of the PRECISION study, which evaluates the effect of the dual endothelin receptor antagonist aprocitentan on blood pressure (BP) in patients with resistant hypertension (RHT) are presented. The study is a blinded, randomized, parallel‐group Phase 3 study and its three‐p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danaietash, Parisa, Verweij, Pierre, Wang, Ji‐Guang, Dresser, George, Kantola, Ilkka, Lawrence, Mary Katherine, Narkiewicz, Krzysztof, Schlaich, Markus, Bellet, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278594/ https://www.ncbi.nlm.nih.gov/pubmed/35686330 http://dx.doi.org/10.1111/jch.14517

Ejemplares similares

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
por: Verweij, Pierre, et al.
Publicado: (2020)

Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
por: Heidari Nejad, Sayeh, et al.
Publicado: (2023)

Aprocitentan: A new development of resistant hypertension
por: Yao, Yao, et al.
Publicado: (2023)

Aprocitentan: New insights
por: Varzideh, Fahimeh, et al.
Publicado: (2022)

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol
por: Chow, Clara K., et al.
Publicado: (2021)

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet
por: Gueneau de Mussy, Pierre, et al.
Publicado: (2020)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime
por: Dąbrowska, Edyta, et al.
Publicado: (2023)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Sildenafil in endotoxin-induced pulmonary hypertension: an experimental study
por: Kemper, Daniella Aparecida Godoi, et al.
Publicado: (2021)

Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease
por: Surma, Stanisław, et al.
Publicado: (2022)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

2224: Characterizing vigilant thoughts and behaviors that disrupt sleep in veterans and utilization of cognitive techniques
por: Katherine Howell, Mary, et al.
Publicado: (2018)

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
por: Lim, Elgene, et al.
Publicado: (2022)

Hypertension, Brain Damage and Cognitive Decline
por: Gąsecki, Dariusz, et al.
Publicado: (2013)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension
por: Wallbach, Manuel, et al.
Publicado: (2022)

Implementing a home-based virtual hypertension programme—a pilot feasibility study
por: Gupta, Aditi, et al.
Publicado: (2022)

Rationale and design of the precise percutaneous coronary intervention plan (P3) study: Prospective evaluation of a virtual computed tomography‐based percutaneous intervention planner
por: Nagumo, Sakura, et al.
Publicado: (2021)

Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2014)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study
por: Matsuda, Akihisa, et al.
Publicado: (2022)

Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry
por: Mahfoud, Felix, et al.
Publicado: (2019)

The sensitivity and specificity of methylene blue spray to identify the parathyroid gland during thyroidectomy
por: Piromchai, Patorn, et al.
Publicado: (2019)

Identifying patterns of kinesiophobia trajectories among COPD patients: A longitudinal study
por: Liang, Facun, et al.
Publicado: (2023)

The potential role of testosterone in hypertension and target organ damage in hypertensive postmenopausal women
por: Li, Ningyin, et al.
Publicado: (2019)

Blood Pressure Management in Acute Ischemic Stroke
por: Gąsecki, Dariusz, et al.
Publicado: (2020)

Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
por: Brigell, Mitchell, et al.
Publicado: (2022)

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study
por: Choi, JungMin, et al.
Publicado: (2021)

Device-based approaches for renal nerve ablation for hypertension and beyond
por: Thorp, Alicia A., et al.
Publicado: (2015)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
por: Tan, Wei Shen, et al.
Publicado: (2020)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

In‐hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial
por: Müllhaupt, Gautier, et al.
Publicado: (2019)

Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial
por: Macias, Victor A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kfsj95m2mn2gglhfbmmrijpuv7